Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals Stock
Hikma Pharmaceuticals dominated the market today, gaining €0.73 (4.920%).
Pros and Cons of Hikma Pharmaceuticals in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
B****
Cons
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hikma Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hikma Pharmaceuticals | 4.920% | -0.403% | 3.056% | -31.296% | -15.682% | -27.255% | -46.619% |
| Viatris Inc. | 0.390% | 0.996% | -1.126% | 77.306% | 11.685% | 30.952% | 8.402% |
| Opko Health Inc. | 0.520% | 3.400% | -1.262% | -18.760% | -11.025% | -27.817% | -71.140% |
| Amicus Therapeutics Inc. | 0.580% | -1.066% | -2.661% | 109.913% | 0.583% | 21.307% | 58.816% |
Comments
Hikma Pharmaceuticals (OTCMKTS:HKMPF) was downgraded by analysts at Barclays PLC to an "underweight" rating.
Show more
Ratings data for HKMPF provided by MarketBeat
Hikma Pharmaceuticals PLC (OTCMKTS: HKMPF) is now covered by analysts at BNP Paribas. They set an "outperform" rating on the stock.
Show more
Ratings data for HKMPF provided by MarketBeat